QianmengYu : I load a piece on Friday. More or less too rush or mistake… Still need a year or two for new acquisitions to be commercialized.

Justin Zacks : Despite the dour forecast for Covid vaccines and antivirals, the stock is trading slightly higher post-results. Expectations of a slowdown may have already been priced in. Pfizer is down about 15% in 2023 its worst start to a year since 2009.
Ex-Covid products, revenue is expected to grow 7% to 9% in 2023. Additional, part of the lower forecast is due to increased R&D spend on the pipeline. Pfizer expects to launch 19 new drugs and indications in the next 18 months.
The view and opinions of the author do not reflect the views of Moomoo Financial Inc. or any of its affiliates. The views and opinions of the author are provided for informational purposes only, do not constitute a recommendation of an investment strategy or to buy, sell, or hold any investment in any form, and are not research reports and should not be used to serve as the basis for any investment decision. All investments involve risk including the loss of principal and past performance does not guarantee future results.